Cameco Stock Is Down 42% From Its Record. Here's How I'd Buy It Around Its Oct. 30 Report.

Cameco shares fell about 42% from their Jan. 28 record close to $78.60 on Oct. 23, despite the long-term uranium price reaching $96.50/lb at September-end, above its 2007 peak. Q2 adjusted EPS declined 75% year over year, while realized uranium prices rose 18% to US$67.79/lb; the company’s 2026 delivery outlook is 29–32 million pounds and its realized-price forecast is C$91–C$96/lb. The article says higher rates and a roughly 40x forward P/E are risks, while potential Westinghouse IPO news could be a catalyst; the author favors staged buying around the Oct. 30 report.

Analysis

The setup is a timing mismatch, not a clean read-through from uranium prices to near-term earnings. Contract repricing can support Cameco (CCO) over several years, but the stock’s premium valuation leaves it exposed to rate-driven multiple compression before that uplift reaches reported results. Deliberately lighter future commitments preserve price optionality, but also make the bullish case dependent on converting today’s strong term market into contracts without sacrificing delivery credibility.

Westinghouse is a separate potential valuation catalyst, not proof of near-term uranium demand. A high IPO valuation could sharpen sum-of-parts interest in both CCO and Brookfield Renewable Partners (BEP.UN), but a paper mark is not cash realization; IPO timing, offering terms, ownership dilution, and post-listing performance matter. A successful listing may also become a “sell the news” event if investors have already capitalized the headline valuation.

Near term, the Oct. 30 report risks looking weak on quarterly earnings even if the full-year trajectory is intact. Over 1–3 months, delivery guidance and evidence of contract repricing matter more than a single quarter’s EPS. Over 6–18 months, sustained term-market strength and Westinghouse’s public-market progress could support the thesis; falling term prices, persistent rate pressure, or execution slippage would undermine it. The contrarian point: the drawdown may overstate operating deterioration, but the premium multiple means it does not automatically make CCO cheap.

Key Decisions for Investors

• Do not chase CCO ahead of the report. Consider staged exposure after results only if management maintains the full-year delivery outlook and realized-price trajectory; size for further multiple compression.
• Treat a Westinghouse IPO as an event catalyst for CCO and BEP.UN, not a base-case valuation floor. Verify timing, offer valuation, dilution, and whether either company signals actual proceeds or a change in capital allocation.
• Falsify the uranium-pricing thesis if term-market strength reverses or CCO cuts delivery/realized-price expectations; those would weaken the case that contract rollovers can translate benchmark prices into earnings.
• If results are soft but guidance holds, distinguish timing and mix effects from deterioration before reducing exposure. If guidance is cut or contract momentum weakens, avoid averaging down solely on the share-price decline.